Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
ICELL GENE THERAPEUTICS INC. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed between 2 distinct examiners and 2 distinct art units, reflecting a varied technical focus for the company's current filings. Peter J Reddig is the busiest examiner for the portfolio, currently managing 1 pending office action. This distribution indicates that the company's active prosecution is not centralized under one person.
With 2 pending office actions assigned to 2 distinct examiners, the company's patent strategy involves multiple points of review. Peter J Reddig's role as the busiest examiner involves 1 pending office action, which is a portion of the total active workload. The involvement of 2 distinct art units suggests that the company's innovations in Biotechnology & Pharmaceuticals are being evaluated by different specialized groups. This spread across 2 distinct examiners and 2 distinct art units requires the company to manage diverse examiner expectations simultaneously.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REDDIG, PETER J | 1 | 58.0% | +40.2% |
| BRISTOL, LYNN ANNE | 1 | 63.4% | +39.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17994787 | CHIMERIC ANTIGEN RECEPTORS (CARs) COMPOSITIONS AND METHODS THEREOF | BRISTOL, LYNN ANNE | 70d |
| 18411101 | COMPOUND CHIMERIC ANTIGEN RECEPTOR (CCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHODS OF USE THEREOF | REDDIG, PETER J | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18411101 | COMPOUND CHIMERIC ANTIGEN RECEPTOR (CCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHODS OF USE THEREOF | REDDIG, PETER J | 1646 | §102DP | Non-Final OA | — | Pending | Jan 12, 2024 |
| 17994787 | CHIMERIC ANTIGEN RECEPTORS (CARs) COMPOSITIONS AND METHODS THEREOF | BRISTOL, LYNN ANNE | 1643 | §112Other | Non-Final OA | 70d | Pending | Nov 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialICELL GENE THERAPEUTICS INC. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Peter J Reddig has the most, with 1 of ICELL GENE THERAPEUTICS INC.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
